Organisation paid for research Program year 2022 Source: CMS Open Payments

Amarillo Heart Group

Neither a doctor nor a teaching hospital

Research payments

$61,679

18 payments

Through program year 2022, Amarillo Heart Group is reported as receiving $61,679 in research payments, across 18 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$33,277	4
2021	Research	$28,105	8
2020	Research	$22	1
2019	Research	$276	5

Breakdown

Who paid Research payments · program years 2019–2022

Boehringer Ingelheim Pharma GmbH & Co.KG $33,311 5 payments
Boehringer Ingelheim International GmbH $28,070 7 payments
Amgen Inc. $196 2 payments
Abbott Laboratories $90 2 payments
Janssen Research & Development, LLC $12 2 payments

Studies the money was for Research payments · program years 2019–2022

Empagliflozin for prevention of HHF and death afte $33,277 4 payments
Empagliflozin for prevention of HHF and death after an AMI $28,105 8 payments
Galactic-Hf $174 1 payment
Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II) (SHIELD II) $90 2 payments
Galactic - HF $22 1 payment
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER) $12 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.